Cited 1 times in
Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김범경 | - |
dc.date.accessioned | 2024-03-22T06:15:41Z | - |
dc.date.available | 2024-03-22T06:15:41Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.issn | 2235-1795 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198485 | - |
dc.description.abstract | Background: Emerging data suggest that outcomes for advanced hepatocellular carcinoma (HCC) treated with sorafenib may have improved over time. We aimed to provide robust, time-To-event estimates of survival outcomes for sorafenib in advanced HCC. Summary: In this systematic review and individual patient data meta-Analysis of randomized-controlled trials (RCTs), we searched MEDLINE and Embase from inception till September 2022 for RCTs that provided data for overall survival (OS) and progression-free survival (PFS) for sorafenib monotherapy as first-line systemic therapy for advanced HCC. We performed a pooled analysis using reconstructed individual participant data from published Kaplan-Meier curves to obtain robust estimates for OS and PFS. Of 1,599 articles identified, 29 studies (5,525 patients) met the inclusion criteria. Overall, the median OS was 10.4 (95% CI: 9.6-11.4) months. Median OS increased over time, from 9.8 (95% CI: 8.8-10.7) months in studies before 2015 to 13.4 (95% CI: 11.03-15.24) months in studies from 2015 onwards (p < 0.001). OS did not differ by trial phase, geographical region, or study design. The overall median PFS was 4.4 (95% CI: 3.9-4.8) months, but PFS did not improve over time. Sensitivity analysis of studies from 2015 and onwards to account for the introduction of direct-Acting antivirals determined that hepatitis C virus was associated with reduced mortality (p < 0.001). There was minimal heterogeneity in the estimates for OS (all I2 ≤ 33). Key Messages: Survival outcomes for sorafenib in advanced HCC have improved over time. These data have important implications for clinical trial design. © 2023 S. Karger AG. All rights reserved. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | S. Karger | - |
dc.relation.isPartOf | LIVER CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Darren Jun Hao Tan | - |
dc.contributor.googleauthor | Ansel Shao Pin Tang | - |
dc.contributor.googleauthor | Wen Hui Lim | - |
dc.contributor.googleauthor | Cheng Han Ng | - |
dc.contributor.googleauthor | Benjamin Nah | - |
dc.contributor.googleauthor | Clarissa Fu | - |
dc.contributor.googleauthor | Jieling Xiao | - |
dc.contributor.googleauthor | Benjamin Koh | - |
dc.contributor.googleauthor | Phoebe Wen Lin Tay | - |
dc.contributor.googleauthor | Eunice X Tan | - |
dc.contributor.googleauthor | Margaret Teng | - |
dc.contributor.googleauthor | Nicholas Syn | - |
dc.contributor.googleauthor | Mark D Muthiah | - |
dc.contributor.googleauthor | Nobuharu Tamaki | - |
dc.contributor.googleauthor | Sung Won Lee | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Thomas Yau | - |
dc.contributor.googleauthor | Arndt Vogel | - |
dc.contributor.googleauthor | Rohit Loomba | - |
dc.contributor.googleauthor | Daniel Q Huang | - |
dc.identifier.doi | 10.1159/000529824 | - |
dc.contributor.localId | A00487 | - |
dc.relation.journalcode | J02170 | - |
dc.identifier.eissn | 1664-5553 | - |
dc.identifier.pmid | 37901764 | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Liver cancer | - |
dc.subject.keyword | Systemic therapy | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.citation.volume | 12 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 445 | - |
dc.citation.endPage | 456 | - |
dc.identifier.bibliographicCitation | LIVER CANCER, Vol.12(5) : 445-456, 2023-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.